A pharmaceutical company may describe an educational grant as independent support. Regulators, accrediting bodies, and experienced compliance teams will ask a more useful question: independent from whom, at which stage, and with what evidence? A policy that says “commercial and medical are separated” is not a control. It is a sentence. The control is the operating model behind it — who receives the request, who reviews it, who approves it, who signs the agreement, who monitors the activity, and who is forbidden from influencing any of those decisions.
That is the practical centre of a medical education grant governance framework. Not optimism. Not tasteful branding. Separation that survives an audit, a difficult internal conversation, and the inevitable request to make the process “a little more flexible.”
Architecting the firewall: separating commercial influence from grant allocation
Medical education grant compliance begins with an organisational decision: commercial objectives cannot govern independent education funding.
This sounds obvious until the process meets reality. Sales teams know where educational gaps exist. Marketing teams know which specialties matter to a brand strategy. Field teams know which institutions are influential. None of that gives them a legitimate role in deciding which educational activities receive funding, which provider is selected, or how the activity is designed.
The HHS Office of Inspector General’s 2003 Compliance Program Guidance for Pharmaceutical Manufacturers established the basic expectation: educational grants must remain independent from commercial influence, and sales and marketing personnel must not influence grant allocation. The point is not merely to prevent an explicit quid pro quo. It is to stop the more common and more defensible-looking version of the same problem — a process in which commercial priorities shape decisions indirectly, through informal recommendations, internal pressure, access to customer intelligence, or selective visibility into pending requests.
That is where the corporate echo chamber becomes dangerous. Everyone can claim that no one made the final decision, while the decision has nevertheless been engineered by the information that reached the reviewers.
A credible firewall should separate at least four functions:
- Request intake: receiving applications through a controlled channel, rather than through account teams or individual commercial contacts.
- Scientific and educational review: assessing the activity against documented medical education grant review criteria.
- Funding approval: authorising the grant through an independent committee or designated medical affairs governance body.
- Execution and monitoring: confirming that the funded activity follows the approved terms and that required documentation is retained.
The names of these functions may differ by organisation. The logic should not.
What the firewall must prevent
A firewall between commercial and medical grants is not achieved by moving the process into a different inbox. It must prevent specific forms of influence. For example:
- Sales or marketing personnel should not select grant recipients.
- Commercial personnel should not rank applications according to customer value, prescribing potential, account importance, or anticipated product uptake.
- Funding should not be conditioned on prescribing, purchasing, formulary placement, access, or any other commercial arrangement.
- Commercial teams should not select or suggest faculty for accredited education.
- The grant decision should not be used to secure access to healthcare professionals or institutions.
- Medical affairs personnel should not use grant governance as a cosmetic route for commercial priorities that cannot withstand direct scrutiny.
The process also needs a record of independence. A committee may be genuinely independent, but if its minutes are vague, its criteria are unpublished internally, and its decisions cannot be reconstructed, the organisation has created a compliance story rather than compliance evidence.
A useful governance record should show:
1. Who submitted the request and through which channel.
2. Which eligibility and educational criteria were applied.
3. Who reviewed the application.
4. Whether any reviewer had a conflict of interest.
5. Why the request was approved, declined, or returned for clarification.
6. Who authorised the payment.
7. What post-award documentation was received.
The discipline here is deliberately unglamorous. Good governance often looks like administrative friction — until the day it becomes the only thing standing between an organisation and a very expensive explanation.
Independence is not a declaration printed in the policy. It is the absence of commercial fingerprints at every meaningful decision point.
The 2022 ACCME Standards: disclosure is not decoration
For organisations supporting accredited continuing medical education in the United States, the ACCME Standards for Integrity and Independence in Accredited Continuing Education are central to the operating model. They took effect on January 1, 2022, replacing the previous Standards for Commercial Support.
The change was not a rebranding exercise. The revised standards sharpened the separation between accredited education and commercial marketing, including tighter requirements around financial relationships, content control, and the eligibility of people who influence educational activities.
One detail is particularly easy to miss: the relevant financial relationship disclosure lookback period increased from 12 months to 24 months. That change affects how organisations evaluate planners, faculty, and others who may control educational content. A governance process built around the old 12-month window is not “nearly compliant.” It is using an outdated control.
The standards also exclude owners and employees of ineligible companies from controlling educational content or serving as planners and faculty. That restriction matters because content independence can be compromised long before a commercial message appears on a slide. Topic selection, learning objectives, case selection, speaker choice, and the framing of evidence all influence the educational outcome.
In practice, the funding organisation should not attempt to solve these issues by drafting increasingly elaborate disclaimers. A disclosure statement does not neutralise control by an ineligible company. Nor does a statement that the faculty member is respected, experienced, or capable of being balanced. The question is structural: who has authority over the education?
A practical review of independence
When managing medical education grant requests, I would expect the review process to distinguish between the commercial supporter and the independent educational provider. The provider should retain responsibility for:
- Educational content and learning objectives.
- Selection of faculty and planners.
- Development and approval of educational materials.
- Delivery of the accredited activity.
- Management of relevant financial relationship disclosures.
- The educational venue and activity format, where those elements affect independence.
This is where many internal processes become confused. A funder can define the broad therapeutic area for which it is willing to support education, subject to its governance model. That does not mean it can dictate the curriculum. A funder can review a proposal for compliance and legitimate use of funds. That does not mean it can rewrite the scientific content. A funder can require documentation. That does not mean it can turn documentation review into a disguised editorial function.
The distinction is narrow in wording and substantial in consequence.
The 24-month lookback and operational consequences
The 24-month disclosure period needs to appear in systems, forms, reviewer guidance, and training — not merely in a policy document that no one opens after onboarding.
A sound workflow will identify:
- Which individuals are subject to financial relationship review.
- What constitutes a relevant financial relationship under the applicable standard.
- How disclosures are collected and validated.
- Who determines whether a relationship affects eligibility or control.
- How the decision is documented.
- What happens when the information is incomplete or changes before the activity.
The last point matters. Education is not frozen at the moment a grant application is approved. Faculty may change. A planner may be added. A provider may revise the activity. If the governance model checks independence once and then disappears into the filing cabinet, it is not managing risk; it is documenting an optimistic moment in time.
Operationalising OIG compliance: from principle to workflow
The HHS OIG guidance is often cited at a high level and applied at a low level. Organisations say they support independent education, then build a process that routes applications through commercial teams because those teams already “own the relationship.” That is precisely the sort of operational shortcut that weakens the firewall.
OIG Advisory Opinion 22-14 adds another important risk signal. It confirmed that grant funding provided directly to entities involved in patient care, rather than to independent accredited education providers, presents heightened risks under the Anti-Kickback Statute.
That does not mean every grant to a patient-care entity is automatically unlawful. It means the risk profile changes, and the governance process must not treat all recipients as interchangeable. A community practice, hospital department, professional association, independent education provider, and patient-care organisation may all request support for educational activities, but they do not create identical compliance questions.
The review should therefore examine the recipient, the proposed activity, the funding pathway, and the relationship between the recipient and the sponsor. Generic approval language will not do much work when the underlying arrangements differ.
Building medical affairs grant review criteria
A grant review committee needs criteria that are specific enough to guide decisions and consistent enough to defend them. “Strategic fit” is usually too vague; it can mean educational need on Monday and sales priority by Friday.
Useful criteria may include:
- Whether the proposed activity addresses a genuine educational need.
- Whether the applicant is eligible to receive support under the organisation’s policy.
- Whether the activity is accredited, and by whom, where accreditation is relevant.
- Whether the educational provider controls content, faculty, planners, and materials.
- Whether the proposal clearly separates education from promotional activity.
- Whether the budget is proportionate to the activity and adequately explained.
- Whether the funding pathway creates additional anti-kickback or inducement concerns.
- Whether relevant financial relationships have been disclosed and managed.
- Whether the proposed activity duplicates existing education without a defensible rationale.
- Whether the applicant can provide appropriate post-activity documentation.
These are not boxes to tick mechanically. They are prompts for a reasoned decision. A committee that approves every plausible application is not generous; it is probably under-governed.
The role of Medical Affairs
Medical Affairs should own or materially control the governance model because the central question is educational and scientific independence, not merely payment processing. That does not make Medical Affairs a substitute commercial function with more tasteful vocabulary.
Medical Affairs must also maintain its own boundaries. It should not use grant review to select institutions for future engagement, identify high-value clinicians, or create a pipeline for field activity. The fact that a request comes through Medical Affairs does not automatically make it non-commercial. Labels are optics; decision rights are substance.
A well-designed process makes inappropriate influence difficult rather than relying on individual restraint. Access should be role-based. Applications should be visible to the people who need to review them, not automatically to every stakeholder with an interest in the account. Committee membership should be documented. Conflicts should be declared. Escalation routes should be clear.
And when a request is declined, the rationale should be intelligible. “Not aligned” is rarely enough. Alignment is one of those corporate words that can mean almost anything while appearing reassuringly precise.
The Letter of Agreement: making independence contractual
A formal Letter of Agreement should be executed before the programme begins. The purpose is not ceremonial. It establishes the boundaries between the commercial supporter and the independent educational provider.
The agreement should state that responsibility for the following rests solely with the independent provider:
- Content.
- Faculty selection.
- Educational materials.
- Venue, where applicable to the provider’s independent control.
- Planning and delivery of the accredited education.
- Management of the activity in accordance with applicable accreditation standards.
This is also where the funding purpose should be made specific. The agreement should identify the supported activity, approved amount or funding terms, permitted use of funds, payment conditions, documentation requirements, and any applicable reporting obligations. Vague language creates room for the sort of interpretive creativity that compliance teams tend to discover at the worst possible moment.
The LOA should not be drafted as a marketing document. The funder’s contribution should be described accurately, without implying ownership of the education. Nor should the agreement give the sponsor approval rights over faculty, slides, learning objectives, or educational messaging if the activity is meant to remain independent.
What the LOA should not quietly contain
Several provisions deserve particular suspicion:
- Rights to approve or reject faculty based on commercial preferences.
- Rights to review educational content for product messaging.
- Requirements that the provider invite named customers or accounts.
- Funding conditions tied to prescribing, purchasing, access, or formulary activity.
- Obligations to provide identifiable attendee data for commercial follow-up.
- Broad promotional rights within an accredited activity.
- Ambiguous language allowing the sponsor to change the programme after approval.
Some organisations attempt to preserve influence through softer language: consultation, collaboration, alignment, input. The vocabulary is gentler; the control can be identical.
The provider may need to share information to demonstrate compliance with the agreement. That is different from granting the sponsor an editorial role. Compliance oversight should verify that the agreed activity occurred and funds were used appropriately. It should not become a backdoor into content control.
The Letter of Agreement should make the boundary harder to cross — not provide a more polished description of where the boundary used to be.
Managing the 30-minute buffer: the detail that exposes the operating model
The ACCME standards require a minimum 30-minute time buffer between accredited continuing education and non-accredited or promotional marketing activities taking place in the same educational setting.
Thirty minutes is not an aesthetic preference. It is an operational control. It requires the organiser to manage schedules, room use, signage, transitions, speaker arrangements, and attendee communications with enough precision that education and promotion are not presented as one continuous commercial experience.
The buffer becomes particularly important at conferences, satellite programmes, hotel venues, and other settings where an educational activity may sit next to product-focused content. A programme can be scientifically sound and still create avoidable risk if the transition is indistinct.
Operational planning should answer straightforward questions:
- When does the accredited activity end?
- When may promotional content begin?
- Are attendees clearly told which activity they are entering?
- Are rooms, materials, and signage distinguishable?
- Are faculty and commercial speakers presented in a way that avoids confusion?
- Does the agenda preserve the full buffer rather than treating it as an aspirational gap?
- Who is responsible for documenting that the separation occurred?
The 30-minute rule also tests whether the organisation understands the difference between separation on paper and separation in the room. A programme that lists two sessions with a nominal gap but continues networking, branded messaging, or promotional discussion in the same space may not deliver the clean boundary the schedule suggests.
The practical answer is not to place every activity in a different building. It is to design the environment deliberately. Separate rooms where feasible. Use clear agendas. Avoid shared educational materials. Make the change in activity visible to attendees. Assign responsibility to someone who is present and empowered to correct the programme if the separation collapses.
Monitoring after approval
Grant governance does not end when the payment is released. Post-award monitoring should be proportionate, but it should exist.
Depending on the activity, the organisation may retain:
- The final programme and educational materials.
- Evidence of accreditation or provider status.
- Faculty and planner information.
- Financial relationship disclosure documentation.
- Attendance or completion records where appropriate.
- A report confirming use of funds.
- Evidence that the 30-minute separation was implemented when relevant.
- Documentation of deviations and corrective actions.
The point is not to create an archival museum of paperwork. It is to preserve the chain of accountability. If the delivered activity differs materially from the approved proposal, the organisation should know why and determine whether the change affects compliance.
A strong process also learns from exceptions. If a provider repeatedly submits incomplete information, changes faculty late, or blurs accredited and promotional programming, that pattern belongs in future risk assessment. Grant governance should be capable of remembering.
A governance model that can survive scrutiny
The most defensible independent medical education funding process is not necessarily the one with the largest committee or the longest policy. It is the one in which responsibility is clear and commercial influence has nowhere to hide.
A practical model usually includes:
1. A controlled intake route that bypasses sales and marketing as decision-makers.
2. Published internal eligibility and review criteria tied to educational independence and compliance risk.
3. A documented review committee with defined membership, authority, and conflict-of-interest procedures.
4. Medical Affairs oversight of scientific and educational governance, without converting the function into a commercial gatekeeper.
5. A formal LOA before programme launch, with independent provider responsibilities stated plainly.
6. Controls for the 24-month financial relationship lookback required under the ACCME standards.
7. A documented 30-minute separation between accredited education and promotional activity in shared settings.
8. Post-award monitoring and records sufficient to reconstruct the decision and the delivered activity.
9. Escalation for higher-risk recipients or funding arrangements, particularly where patient-care entities are involved.
10. Training that explains decision rights, rather than repeating slogans about integrity.
The framework should also be tested against uncomfortable scenarios. What happens when a senior commercial leader recommends a prestigious institution? What happens when an important customer asks whether funding is available? What happens when a provider wants the sponsor to approve faculty “for accuracy”? What happens when the educational programme is scheduled beside a promotional session and the 30-minute gap disappears?
If the answer depends on finding the right person in the moment, the system is fragile. If the answer is already embedded in the process, the organisation may have something more valuable than a polished policy: actual governance.
The pragmatic conclusion
Medical education grants do not become independent because the funding is routed through Medical Affairs, described as educational, or accompanied by a paragraph about scientific integrity. They become defensible when commercial personnel cannot influence allocation, independent providers control the education, financial relationships are assessed over the correct 24-month period, agreements define responsibilities before the programme begins, and operational details such as the 30-minute buffer are treated as controls rather than calendar decoration.
The industry has no shortage of language for independence. It has less appetite for the consequences of independence — declining a strategically attractive request, refusing a preferred speaker, separating a lucrative event from accredited education, or accepting that the best governance outcome may be a grant that does not advance a brand objective.
That is the test. A medical education grant governance framework should not merely make compliant support possible. It should make commercial interference conspicuous, difficult, and documentable.
Anything less is not a firewall. It is optics with an administrative budget.